ElevateBio Welcomes Larry Lockwood, Ph.D. as CCO
ElevateBio Expands Leadership with New Chief Commercial Officer
ElevateBio, a pioneering company driving advancements in genetic medicines, has appointed Larry Lockwood, Ph.D., as its Chief Commercial Officer. With over 20 years of leadership and expertise in the biotech sector, Dr. Lockwood is set to propel ElevateBio's commercial strategies and revenue growth.
Dr. Lockwood's Vision for Commercial Strategy
In his new role, Dr. Lockwood will be instrumental in developing commercial strategies that enhance ElevateBio's partnerships, particularly at BaseCamp, the company's cGMP manufacturing service. He is charged with monetizing technologies from Life Edit, ElevateBio’s gene editing and research platform. His wealth of experience in transforming technology solutions into substantial commercial contracts positions him well to capture greater market share in the fast-evolving field of genetic medicine.
Statements from ElevateBio Leadership
Ger Brophy, the CEO of ElevateBio, expressed enthusiasm about Dr. Lockwood's timing in joining the company: "Larry is joining ElevateBio at a key moment along our growth trajectory, as BaseCamp is expanding its capabilities and impact while Life Edit continues to advance its gene editing platform. His proven ability to drive significant revenue growth for CDMOs and his extensive customer support experience across major continental markets makes him the ideal candidate to lead our commercial efforts."
Dr. Lockwood’s Remarks on Genetic Medicine
Dr. Lockwood shared his insights on the genetic medicines market, highlighting the critical need for innovative technologies alongside scalable manufacturing reliability. "This is an exciting opportunity to leverage ElevateBio's integrated approach to provide biopharmaceutical partners with comprehensive solutions for their therapy developments. By demonstrating our value from the early discovery stages to commercial-scale manufacturing, we aim to redefine the genetic medicine landscape while establishing a solid commercial foothold for the future," he remarked.
Prior Experience and Expertise
Before joining ElevateBio, Dr. Lockwood held key leadership roles at Aldevron, a part of Danaher Life Sciences. His most recent position was as Global Head of CDMO Strategy, where he was responsible for shaping go-to-market strategies and building strategic alliances that substantially improved client engagement. His earlier roles also included significant positions in sales and business development at notable biotech firms including RoosterBio, Horizon Discovery, Lonza Biologics, and AMRI. Dr. Lockwood earned his Ph.D. in Organic Chemistry from Rensselaer Polytechnic Institute and his B.S. in Chemistry from Towson State University.
About ElevateBio
ElevateBio is committed to revolutionizing the landscape of genetic medicines by harnessing cutting-edge technologies and extensive manufacturing capabilities. The company collaborates with partners to expedite the development of transformative therapies. The ElevateBio ecosystem merges Life Edit, which specializes in gene editing, with BaseCamp, focusing on comprehensive genetic medicine process development and manufacturing to accelerate therapeutic advancements.
Contact Information
For more information about ElevateBio or to inquire further, here are the relevant contacts:
Investor Contact:
Catherine Hu
Email: chu@elevate.bio
Media Contact:
DJ Webster
Email: dwebster@elevate.bio
Frequently Asked Questions
What is ElevateBio's primary focus?
ElevateBio is focused on driving innovation in genetic medicines through advanced technologies and manufacturing capabilities.
Who is the new Chief Commercial Officer of ElevateBio?
Larry Lockwood, Ph.D., has been appointed as the Chief Commercial Officer at ElevateBio.
What experience does Dr. Lockwood bring to ElevateBio?
Dr. Lockwood has over 20 years of experience in biotech, with a strong track record in commercial strategy and building global partnerships.
What is ElevateBio's ecosystem?
The ElevateBio ecosystem combines its gene editing business, Life Edit, with BaseCamp, its cGMP manufacturing service, to support therapeutic development.
How can I learn more about ElevateBio?
You can visit ElevateBio's official website or follow them on social media platforms for more information.
About The Author
Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
